LEXINGTON, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ), a company developing innovative diagnostic products to improve patient health, today announced the Company’s T2 Magnetic Resonance (T2MR ® ) technology in detecting early-stage Lyme disease and T2Candida ® Panel in rapid sepsis detection will be the focus of five poster presentations during IDWeek 2016. The conference, hosted by the Infectious Diseases Society of America, will take place October 26-30 in New Orleans.
The schedule for presentations by T2 Biosystems and its collaborators is as follows:
205. Detection of Borrelia in Early-Stage Lyme Disease Using T2 Magnetic Resonance Session: Poster Abstract Session: Diagnostics: Bacteriology, Sequencing, and Resistance Presenter: T2 Biosystems Date: Thursday, October 27 Room: Poster Hall
1560. Antifungal Prescribing During Initial Implementation of Candidemia Early Detection and Species Identification Testing with T2 Candida Panel Session: Poster Abstract Session: Mycology: Diagnostic Presenter: Riverside Community Hospital Date: Friday, October 28 Room: Poster Hall
1567. Utilization of T2Candida Panel for the rapid detection of Candida species in a large community hospital Session: Poster Abstract Session: Mycology: Diagnostic Presenter: Huntsville Hospital Date: Friday, October 28 Room: Poster Hall
1569. T2 Magnetic Resonance Improves Timely Management of Candidemia Session: Poster Abstract Session: Mycology: Diagnostic Presenter: Henry Ford Hospital Date: Friday, October 28 Room: Poster Hall
1571. Novel T2 Magnetic Resonance Assay Compared to Standard Blood Cultures for Detection of Candidemia Session: Poster Abstract Session: Mycology: Diagnostic Presenter: Henry Ford Hospital Date: Friday, October 28 Room: Poster Hall
About T2 Biosystems T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com .
Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. For more information on risk factors for T2 Biosystems, Inc.’s business, please refer to the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016, under the heading “Risk Factors,” and other filings the Company makes with the Securities and Exchange Commission from time to time. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.
Media Contact: Susan Heins, Pure Communications susan@purecommunicationsinc.com 864.286.9597 Investor Contact: Matt Clawson, Pure Communications matt@purecommunicationsinc.com 949-370-8500
